[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Shi et al., 2022 - Google Patents

One-step synthesis of site-specific antibody–drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates

Shi et al., 2022

View HTML
Document ID
13542252612901852195
Author
Shi W
Li W
Zhang J
Li T
Song Y
Zeng Y
Dong Q
Lin Z
Gong L
Fan S
Tang F
Huang W
Publication year
Publication venue
Acta Pharmaceutica Sinica B

External Links

Snippet

Glycosite-specific antibody‒drug conjugatess (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with two or more enzymes, which limits the substrate diversification and complicates the …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups

Similar Documents

Publication Publication Date Title
Shi et al. One-step synthesis of site-specific antibody–drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates
AU2020220172B2 (en) Site-specific antibody-drug glycoconjugates and methods
Tang et al. One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
EP2935611B1 (en) Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP3057618B1 (en) Glycoengineered antibody, antibody-conjugate and methods for their preparation
US20190225706A1 (en) Modified glycoprotein, protein-conjugate and process for the preparation thereof
EP3058083B1 (en) Modified glycoprotein, protein-conjugate and process for the preparation thereof
CN107810273A (en) With for or derived from β (1,4) N acetylgalactosamine transferases glycosyl transferase modified glucoprotein method
WO2022037665A1 (en) Site-specific antibody conjugates and the methods for preparation of the same
EP4279089A1 (en) Disaccharide linker, disaccharide-small molecule drug conjugate and sugar chain fixed-point antibody-drug conjugate, and preparation method therefor and use thereof
US20240398960A1 (en) Immobilized endoglycosidase fusion protein and use thereof
US11591408B2 (en) Antibody glycoconjugates and methods of production and use
EP4458961A1 (en) Isolated polypeptide and use thereof
WO2023065137A1 (en) Site-specific glycoprotein conjugates and methods for making the same
KR20240135561A (en) Method of antibody-drug conjugates using method of site-specific labeling antibody
WO2025067393A1 (en) Disaccharide-acylhydrazone or disaccharide-hydrazide linker, glyco-engineered antibody and sugar-chain site-directed antibody-drug conjugate based on same, and use thereof